Resources Repository
-
ArticlePublication 2022Comparative Health Systems Analysis of Differences in Catastrophic Health Expenditure
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications …
The growing burden of non-communicable diseases (NCDs) in low- and middle-income countries may have implications for health system performance in the area of financial risk protection, as measured by catastrophic health expenditure (CHE). This article compares non-communicable diseases catastrophic health expenditure to the CHE cases caused by communicable diseases across health systems to examine whether: (1) disease burden and catastrophic health expenditure are linked, (2) Catastrophic health expenditures secondary to NCDs disproportionately affect wealthier households and (3) whether the drivers…
Evidence Synthesis | Chronic Disease/Risk | Costing Methods | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2017Extended Cost-Effectiveness Analyses of Cardiovascular Risk Factor Reduction Policies
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease …
This chapter summarizes lessons learned from three extended cost-effectiveness analyses (ECEAs) conducted on cardiovascular disease (CVD) risk factor reduction policies, specifically highlighting new insights into the differential impacts of well-established CVD prevention interventions. Tobacco taxation, salt reduction, and primary prevention of CVD in high-risk individuals remain widely regarded as best buys in global noncommunicable disease policy, and the ECEAs confirm the findings of previous CEAs, namely, that these interventions will likely result in large health…
Evidence Synthesis | Chronic Disease/Risk | Priority Setting/Ethics | Cost-Effectiveness Analysis | Health/Medicine | Global -
ArticlePublication 2019Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan
This study investigates the feasibility and cost of hepatitis C virus (HCV) elimination in Pakistan …
This study investigates the feasibility and cost of hepatitis C virus (HCV) elimination in Pakistan using a decision analytical model and microsimulation techniques from 2015 to 2030. Various scenarios, including the status quo and seven elimination strategies, were evaluated based on Pakistan-specific variables. Main outcomes included trends in HCV prevalence, mortality, disability-adjusted life-years, and total costs of HCV care. Results suggest that to achieve HCV elimination by 2030, significant scale-up of testing and treatment is…
Decision Analysis | Chronic Disease/Risk | Infectious Diseases | Health/Medicine | Asia & Pacific -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
Decision Analysis | Chronic Disease/Risk | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Health/Medicine | North America -
ArticlePublication 2017Benefit and Harm of Intensive Blood Pressure Treatment: Derivation and Validation of Risk Models Using Data from the Sprint and Accord Trials
Intensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) events but can cause some …
Intensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) events but can cause some serious adverse events. The authors sought to create risk calculators to estimate individual patients’ chances of benefit and harm from intensive treatment. They developed statistical models of cardiovascular events and serious adverse events from individual participant data from the Systolic Blood Pressure Intervention Trial (SPRINT) of intensive blood pressure treatment (N = 9,069 with complete covariate data) and validated them…
Evidence Synthesis | Chronic Disease/Risk | Probability/Bayes | Health Outcomes -
OrganizationWeb Portal 2024American Public Health Association
The American Public Health Association (APHA), was founded in 1872 dedicated to improving the health …
The American Public Health Association (APHA), was founded in 1872 dedicated to improving the health of all U.S. residents. Two of the Association’s most important functions are advocacy for adoption by the government of the most current scientific advances relevant to public health, and public education on how to improve community health. Along with these efforts, they have also campaigned for developing well-organized health departments at both the federal and local levels. In 1966, APHA…
Evidence Synthesis | Chronic Disease/Risk | Health Outcomes | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Mental Health | Injuries/Accidents | Environmental Health | Health Systems | Policy/Regulation | Health/Medicine | Global | North America -
OrganizationWeb Portal 2024Institute for Clinical and Economic Review (ICER)
ICER is a non-profit organization that evaluates evidence on a range of topics including the value …
ICER is a non-profit organization that evaluates evidence on a range of topics including the value of medical tests, treatments and delivery system innovations and moves that evidence into action to improve the health care system. To accomplish this goal ICER performs analyses on effectiveness and costs, supports specific programs, and develops reports using innovative methods that make it easier to translate evidence into decisions that can align efforts to use evidence to drive improvements in both…
Evidence Synthesis | Chronic Disease/Risk | Preferences/Values | Priority Setting/Ethics | Value of Information | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Mental Health | Health Systems | Business/Industry | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | North America | Europe -
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Decision Analysis | Chronic Disease/Risk | Costing Methods | Health Outcomes | Test Performance | Cost-Effectiveness Analysis | Technology Assessment | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | North America -
ArticlePublication 2016Quality Improvement for Cardiovascular Disease Care in Low- and Middle-Income Countries: A Systematic Review
The majority of global cardiovascular disease (CVD) burden falls on people living in low- and …
The majority of global cardiovascular disease (CVD) burden falls on people living in low- and middle-income countries (LMICs). As part of the Disease Control Priorities Three (DCP3) Study efforts addressing quality improvement, the authors reviewed and summarized currently available evidence on interventions to improve quality of clinic-based CVD prevention and management in LMICs. Using a narrative review of published comparative clinical trials that evaluated efficacy or effectiveness of clinic-based CVD prevention and management quality improvement…
Evidence Synthesis | Chronic Disease/Risk | Health Outcomes | Health Systems | Health/Medicine | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific